• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The University of Kansas - Developmental Therapeutics Review - Q4 2010 Product Image

The University of Kansas - Developmental Therapeutics Review - Q4 2010

  • Published: December 2010
  • Region: Kansas
  • 72 pages
  • Global Markets Direct

The University of Kansas – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “The University of Kansas – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by The University of Kansas.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The University of Kansas with complete READ MORE >



List of Tables
List of Figures
The University of Kansas Snapshot
The University of Kansas Overview
Key Information
Key Facts
The University of Kansas – Research and Development Overview
Key Therapeutic Areas
The University of Kansas – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The University of Kansas – Pipeline Products Glance
The University of Kansas – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The University of Kansas Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
The University of Kansas – Drug Profiles
Arimoclomol
Product Description
Mechanism of Action
R&D Progress
Arimoclomol for Inclusion Body Myositis
Product Description
Mechanism of Action
R&D Progress
Gabapentin
Product Description
Mechanism of Action
R&D Progress
5-Azacitidine + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Acolbifene
Product Description
Mechanism of Action
R&D Progress
aprepitant + carmustine + cyclophosphamide + cytarabine + dexamethasone + etoposide + melphalan + palonosetron hydrochloride
Product Description
Mechanism of Action
R&D Progress
aprepitant + carmustine + cyclophosphamide + cytarabine + dexamethasone + etoposide + palonosetron hydrochloride + autologous hematopoietic stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
aprepitant + dexamethasone + melphalan + palonosetron hydrochloride + autologous hematopoietic stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
celecoxib
Product Description
Mechanism of Action
R&D Progress
D-cycloserine
Product Description
Mechanism of Action
R&D Progress
Doxil + Thalidomide + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Estradiol + Estriol + Progesterone
Product Description
Mechanism of Action
R&D Progress
Estradiol + Progesterone
Product Description
Mechanism of Action
R&D Progress
Imatinib mesylate + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Insulin Aspart
Product Description
Mechanism of Action
R&D Progress
lapatinib
Product Description
Mechanism of Action
R&D Progress
Letrozole 2.5 mg for Breast Cancer
Product Description
Mechanism of Action
R&D Progress
Methotrexate
Product Description
Mechanism of Action
R&D Progress
nab-paclitaxel + trastuzumab + Doxorubicin + cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Docetaxel + Cetuximab
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Trastuzumab + Everolimus
Product Description
Mechanism of Action
R&D Progress
Palonosetron + Aprepitant + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Pemetrexed + Cisplatin + Dalotuzumab
Product Description
Mechanism of Action
R&D Progress
Pyridoxamine
Product Description
Mechanism of Action
R&D Progress
Rituximab
Product Description
Mechanism of Action
R&D Progress
Arzoxifene Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Azacitidine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Decitabine + PKC412
Product Description
Mechanism of Action
R&D Progress
Diindolylmethane
Product Description
Mechanism of Action
R&D Progress
Diindolylmethane in Healthy Nonsmokers
Product Description
Mechanism of Action
R&D Progress
Indole-3-Carbinol
Product Description
Mechanism of Action
R&D Progress
Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Vidaza + Cisplatin
Product Description
Mechanism of Action
R&D Progress
The University of Kansas – Pipeline Analysis
The University of Kansas – Pipeline Products by Therapeutic Class
The University of Kansas Pipeline Products By Target
The University of Kansas – Pipeline Products by Route of Administration
The University of Kansas – Pipeline Products by Molecule Type
The University of Kansas – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS